LIMK1 and chronic myelogenous leukemia, BCR-ABL1 positive: Therefore, blocking PAK activity may affect the CML cell survival in two ways: (i) by decreasing the activity of LIMK which will result in the reduction of ROS generation especially in CML stem cells and (ii) by induction of apoptosis in CML cells.